REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total ablative strategies as part of routine clinical care. The registry does not assign treatment. Radiotherapy technique, dose, systemic therapy, surgery, metastasis-directed therapy, imaging, and follow-up are selected by the treating multidisciplinary team according to local standards and patient-specific factors. The registry will collect harmonized retrospective and prospective data on disease characteristics, prior radiotherapy, recurrence pattern, reirradiation or ablative treatment exposure, response, progression, survival, severe treatment-related morbidity, fistula events, and patient-reported outcomes where available.
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
In this phase III study, the primary objective is to test with a one-sided significance of 5% whether for the treatment of small cell lung cancer (SCLC) patients, brain MRI surveillance alone is non-inferior in terms of overall survival compared to prophylactic cranial irradiation (PCI) combined with brain MRI surveillance in the entire study population.
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
About the trial
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its deoxyribonucleic acid (DNA) and may kill tumor cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual care treatment alone in stabilizing and lengthening survival time in patients with stage III non-squamous NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem histologiczne lub cytologiczne raka płuca typu gruczolakorak lub rak wielkokomórkowy
- •Zaawansowany rak płuca stopnia IIIA, IIIB lub IIIC (bez przerzutów na inne narządy)
- •Co najmniej jeden guz widoczny na badaniach obrazowych (przynajmniej 2 cm na zdjęciu rentgenowskim lub 1 cm na tomografii/MRI)
- •Wiek co najmniej 18 lat
- •Masa ciała powyżej 30 kg w dobrym stanie ogólnym
- •Dostateczna liczba białych krwinek (≥3000/mcL), hemoglobiny (≥9,0 g/dL) i płytek krwi (≥150 000/mcL)
- •Wcześniejsza operacja lub część chemioterapii jest dozwolona
- •Brak wcześniejszej chemioterapii skojarzonej z promieniowaniem do tego obszaru
✗ Disqualifies
- •Inne rodzaje raka płuca niż określone w kryteriach włączenia
- •Wiek poniżej 18 lat
- •Masa ciała 30 kg lub mniej albo złe wyniki badań krwi
- •Wcześniejsze promieniowanie tego samego obszaru płuc
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (34)
Keck Medicine of USC Buena Park
Buena Park, United States
City of Hope Comprehensive Cancer Center
Duarte, United States
City of Hope at Irvine Lennar
Irvine, United States
City of Hope Antelope Valley
Lancaster, United States
Los Angeles General Medical Center
Los Angeles, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
City of Hope South Pasadena
South Pasadena, United States
City of Hope Upland
Upland, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, United States
UF Health Cancer Institute - Gainesville
Gainesville, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, United States
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
UC Comprehensive Cancer Center at Silver Cross
New Lenox, United States
University of Chicago Medicine-Orland Park
Orland Park, United States
UChicago Medicine Northwest Indiana
Crown Point, United States
Jersey City Medical Center
Jersey City, United States
Cooperman Barnabas Medical Center
Livingston, United States
Monmouth Medical Center
Long Branch, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Newark Beth Israel Medical Center
Newark, United States
Robert Wood Johnson University Hospital Somerset
Somerville, United States
Community Medical Center
Toms River, United States
Montefiore Medical Center-Einstein Campus
The Bronx, United States
Montefiore Medical Center - Moses Campus
The Bronx, United States
Wake Forest University Health Sciences
Winston-Salem, United States
Case Western Reserve University
Cleveland, United States
MetroHealth Medical Center
Cleveland, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
University of Texas Medical Branch
Galveston, United States
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.